Leica Biosystems, AstraZeneca and Daiichi Sankyo have expanded their strategic collaboration to develop an AI-enabled immunohistochemistry assay and computational pathology solution for evaluating the TROP2 Normalised Membrane Ratio biomarker in NSCLC, aiming to advance biomarker-driven cancer research and future precision medicine approaches.<br />
Computational Pathology | 01/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy